Alnylam Pharmaceuticals ALNY Net product revenues — Accounts Receivable

Similar metrics at other companies

ELANProduct Sales — Accounts Receivable

$131M+10.1%

HGVOther receivables — Accounts Receivable

$0-100%

HGVTax receivables — Accounts Receivable

$69M-41.5%

CZROther — Accounts Receivable

$181M-5.2%

CZRCasino — Accounts Receivable

$178M-0.6%

LVWRSTACYC — Accounts Receivable

$6K-14.3%

FAQ

What is Alnylam Pharmaceuticals's net product revenues — accounts receivable?

Alnylam Pharmaceuticals (ALNY) reported net product revenues — accounts receivable of $787.8M in Q2 2026.

How has Alnylam Pharmaceuticals's net product revenues — accounts receivable changed year-over-year?

Alnylam Pharmaceuticals's net product revenues — accounts receivable increased by 66.0% year-over-year, from $474.7M to $787.8M.

What is the long-term trend for Alnylam Pharmaceuticals's net product revenues — accounts receivable?

Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's net product revenues — accounts receivable has grown at a 46.0% compound annual growth rate (CAGR), from $445.94M to $2.03B.

What does net product revenues — accounts receivable mean?

This metric represents the balance of outstanding payments owed by customers for pharmaceutical products delivered, adjusted for potential credit losses and allowances. It provides insight into the company's ability to collect cash from its commercial activities and the credit quality of its customer base. Monitoring this balance helps assess the efficiency of the revenue cycle and potential liquidity risks associated with product sales.